ERBB2 and breast cancer: However, recently two ongoing trials, the APTneo and Impassion 050, started the enrollment of HER2+ BC PD-L1 unselected patients for the neoadjuvant setting and are comparing atezolizumab plus double block with trastuzumab and pertuzumab plus chemotherapy to double block plus chemotherapy alone.